Efficacy of Naldemedine on Intestinal Hypomotility and Adhesions in Rodent Models of Postoperative Ileus

Area of Science:

• Gastroenterology
• Pharmacology
• Surgical Research

Background:

• Postoperative ileus (POI) significantly impacts patient quality of life (QOL) due to extended hospital stays and readmissions.
• Alvimopan is the sole approved therapeutic agent for POI, acting as a peripheral μ-opioid receptor antagonist.

Purpose of the Study:

• To evaluate the efficacy of naldemedine, a distinct peripheral μ-opioid receptor antagonist, in rodent models of postoperative intestinal hypomotility and adhesion.
• To compare naldemedine's therapeutic effects against those of alvimopan.

Main Methods:

• Rodent models were utilized to assess the impact of naldemedine and alvimopan on intestinal motility following mechanical irritation.
• The efficacy of both drugs in mitigating postoperative adhesions induced by chemical agents was evaluated in rats.

Main Results:

• Both naldemedine (0.3 mg/kg) and alvimopan (3 mg/kg) significantly counteracted the reduction in intestinal motility in mice (p < 0.01).
• Naldemedine (1 mg/kg) demonstrated a significant reduction in adhesion length in rats (p < 0.05), while alvimopan (3 mg/kg) also significantly decreased adhesion ratios (p < 0.01).

Conclusions:

• Naldemedine exhibits significant efficacy in addressing both postoperative intestinal hypomotility and adhesions in preclinical rodent models.
• These findings support naldemedine as a promising therapeutic candidate for managing postoperative ileus, offering an alternative to existing treatments.